Abeona Therapeutics announces FDA approval of Zevaskyn

Abeona Therapeutics (ABEO) announced the U.S. FDA has approved Zevaskyn gene-modified cellular sheets, also known as pz-cel, as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa, a serious and debilitating genetic skin disease. There is no cure for RDEB and Zevaskyn is the only FDA-approved product to treat RDEB wounds with a single application.